Australia Genetic Testing Market Size, Share, and COVID-19 Impact Analysis, By Type (Predictive and Presymptomatic Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, and Others), By Application (Cancer Diagnosis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, and Others), and Australia Genetic Testing Market Insights, Industry Trend, Forecasts to 2035

Australia Genetic Testing Market Insights Forecasts to 2035

• The Australia Genetic Testing Market Size Was Estimated at USD 342.6 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 10.93% from 2025 to 2035
• The Australia Genetic Testing Market Size is Expected to Reach USD 1072.3 Million by 2035

According to a research report published by Spherical Insights & Consulting, the Australia genetic testing market size is anticipated to reach USD 1072.3 million by 2035, growing at a CAGR of 10.93% from 2025 to 2035. The genetic testing market in Australia is driven by rising rates of genetic abnormalities, increased need for personalized medicine, growing awareness of early disease identification, improvements in genomic technology, and improving healthcare infrastructure.

Market Overview

The Australia genetic testing market refers to the industry that analyzes DNA, RNA and proteins to identify genetic disorders, inherited conditions and disease predispositions. Clinical diagnostics, personalized medicine, prenatal and newborn screening, oncology, pharmacogenomics and ancestry testing and research are among the applications. Genetic testing helps healthcare providers make informed treatment decisions while enabling early disease detection and supporting preventive healthcare, and facilitating drug development and precision medicine progress.

The Australia genetic testing market is supported by government initiatives through Medicare rebates, which provide approximately AUD 148.5 million for advanced genetic tests and through the Genomics Health Futures Mission, which provides funding of AUD 500 million for genomic research. Additional support includes MRFF grants, which provide approximately AUD 57 million for AI-driven diagnostics and policies preventing insurers from using genetic results, which together create an environment that promotes personalized healthcare solutions.

Report Coverage

This research report categorizes the market for the Australia genetic testing market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Australia genetic testing market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Australia genetic testing market.

Driving Factors

The genetic testing market in Australia is driven by the increased hereditary and chronic disease cases, together with enhanced disease detection methods and rising needs for personalized medical treatments. The accuracy and accessibility of tests receive improvements through technological progress in genomic sequencing and artificial intelligence integration, and bioinformatics development. The growth of the market depends on expanded healthcare facilities, together with government programs that support testing and increased patient acceptance of testing.

Restraining Factors

The genetic testing market in Australia is mostly constrained by the high expenses required for advanced testing procedures, which combine with limited insurance reimbursement, ethical and privacy issues and the presence of untrained genetic counsellors and the complicated nature of regulatory processes, which together create barriers that prevent patient access to testing.

Market Segmentation

The Australia genetic testing market share is classified into type and application.

• The predictive and presymptomatic testing segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Australia genetic testing market is segmented by type into predictive and presymptomatic testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, and others. Among these, the predictive and presymptomatic testing segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. Preventive healthcare, individualized treatment planning, and risk management are made possible by this, which encourages widespread adoption among patients and healthcare professionals looking to proactively prevent disease. As a result, this market segment sees growth and revenue.

• The cancer diagnosis segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. 

The Australia genetic testing market is segmented by application into cancer diagnosis, genetic disease diagnosis, cardiovascular disease diagnosis, and others. Among these, the cancer diagnosis segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. The increased incidence of cancer and the growing use of genetic profiling for targeted medicines, individualized treatment planning, and early detection are to blame. Demand for cancer-related genetic testing is driven by patients' and healthcare professionals' growing understanding of precision oncology.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Australia genetic testing market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Virtus Genetics
• Rosalind Genetics
• Fulgent Australia
• Genomic Diagnostics
• AGRF Clinical
• Lumi Health
• Sonic Healthcare
• Virtus Health
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments:

• In September 2025, Bupa launched a genetic testing program for pharmaceutical response in Australia, providing pharmacogenomic tests to health insurance members at no cost and lowering public costs.

Market Segment

This study forecasts revenue at the Australia, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Australia genetic testing market based on the below-mentioned segments:

Australia Genetic Testing Market, By Type

• Predictive and Presymptomatic Testing
• Carrier Testing
• Prenatal and Newborn Testing
• Diagnostic Testing
• Pharmacogenomic Testing
• Others

Australia Genetic Testing Market, By Application

• Cancer Diagnosis
• Genetic Disease Diagnosis
• Cardiovascular Disease Diagnosis
• Others